We play an active role in breaking down and analyzing current events in the healthcare industry for our members, policy influencers and the Canadian public.
Our team produces media releases, reports, policy papers and other forms of informative content to keep stakeholders up to date on the most pressing issues facing our industry. Here in our resources section, you’ll be able to find our most recent work.
Cost Drivers Analysis of Private Drug Plans in Canada 2021
Making Canada an International Life Sciences Leader (March 2021)
2016-2019 Analysis of Private Drug Claim Cost Drivers
2016-2019 Analysis of Private Drug Claim Cost Drivers (French Executive Summary).
2019 Annual Report
Cost Drivers Analysis of Private Drug Plans in Canada 2016-2018
Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans (March 2019)
Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications (February 2019)
EY Report: An assessment of Canada’s current and potential future attractiveness as a launch destination for innovative medicines (January 2019)
2018 Annual Report
Real World Evidence Workshop: Industry Input – IMC/BIOTECanada Working Group (2018)
Guide to Providing Clinician Input and Feedback with the pCODR Program (2018)
Value Demonstration with Private Payers Adherence to Treatment & Employer Economic Impact: Literature Review (2018)
Private Drug Plan Drug Cost Forecast (2017-2019)
Cost Drivers Analysis of Private Drug Plans in Canada 2012-2016
Understanding the Gap: A Pan-Canadian Analysis of Prescription Drug Insurance Coverage
2017 Annual Report
Nanos: Prescription Use Survey Summary
Data Analytics and Members’ Economic Footprint and Impact in Canada
Private Drug Plan Drug Cost Forecast (2016-2018)
Making Canada Better 2017 - Conference Summary Report
2016 Annual Report
Access to New Medicines in Public Drug Plans: Canada and Comparable Countries - 2016 Annual Report
